1. Introduction {#sec1-ijms-19-03415}
===============

The pancreas is a key organ involved in digestion and endocrine functions, located in the retroperitoneal space, and measures approximately 15--20 cm in length. The pancreatic duct, that runs along the organ, connects to the duodenum. One major function of the pancreas is digestion of proteins, fats, and carbohydrates by enzymes released through the duct. A second important role of the pancreas is endocrine activity mediated by several hormones, such as insulin, released from the pancreatic glands to the blood circulation, which help maintain the homeostasis in the body. Major diseases of the pancreas include pancreatitis, pancreatic cancer, cystic diseases, pancreatic divisum, islet cell tumors, endocrine tumors, and diabetes mellitus \[[@B1-ijms-19-03415]\].

Among the pathologies involving the pancreas, pancreatic cancer is one of the leading causes of the cancer-related deaths globally and currently is the fourth cause of cancer-related mortalities in the United States \[[@B2-ijms-19-03415]\]. Pancreatic ductal adenocarcinoma, the most common histological type, has a poor prognosis and aggressive growth pattern \[[@B3-ijms-19-03415]\]. Although poor glycemic control and weight loss in patients with long-standing diabetes were proposed as useful markers for pancreatic cancer \[[@B4-ijms-19-03415]\], there are currently no markers or strategies that can detect the tumor in the early phase. In addition, although depletion of adipose and skeletal muscle tissues in the early stages of cancer is common, recent evidence suggests that early loss of peripheral tissue in association with pancreatic cancer may not impair survival \[[@B5-ijms-19-03415]\]; therefore, a better understanding of the mechanism underlying the progression of this aggressive cancer is essential. Recent epidemiological studies clearly show that the mortality rate of pancreatic cancer is not declining, and pancreatic cancer is estimated to become the second cause of cancer-related deaths by 2030 \[[@B6-ijms-19-03415]\]. Therefore, significant effort is spent on the development of novel therapeutic options for this devastating disease.

Although several novel chemotherapeutic compounds, including nab-paclitaxel and liposomal irinotecan, and chemotherapy regimens, such as FOLFIRINOX, have been successfully tested in clinical trials as conventional treatment options \[[@B7-ijms-19-03415]\], the prognosis remains poor \[[@B8-ijms-19-03415]\]. To improve the prognosis of pancreatic cancer, the number of basic researches and clinical trials are increasing \[[@B7-ijms-19-03415]\]. In addition, the comprehensive precision medicine tools for therapeutic options that have been implemented in both the community and academic areas \[[@B9-ijms-19-03415]\] have led to better progression-free survival rates in patients receiving matched therapy.

In a disease where novel therapeutic innovations are sorely needed, combining novel therapies, including gene and cell therapy approaches, with the currently available cytotoxic chemotherapeutic drugs and radiation therapy, provides hope for better outcomes in patients with advanced-stage pancreatic cancer. Among such potentially innovative treatment approaches, gene therapy offers a promising avenue based on the results of several completed and ongoing clinical trials. The summaries of these studies are shown in [Table 1](#ijms-19-03415-t001){ref-type="table"} and [Table 2](#ijms-19-03415-t002){ref-type="table"}.

Preclinical studies have led to a better understanding of pancreatic cancer, as well as potential therapeutic target genes, including tumor suppressor genes, antiangiogenic and pro-apoptotic genes, and suicide genes \[[@B10-ijms-19-03415]\]. A study including 3030 patients with pancreatic cancer showed significant associations with germline mutations in *CDKN2A*, *TP53*, *MLH1*, *BRCA2*, *ATM*, and *BRCA1* and the risk of the cancer occurrence \[[@B11-ijms-19-03415]\]. Similar results have been reported in studies focusing on the role of *KRAS* gene in tumor development \[[@B12-ijms-19-03415]\], and research on inactivation of the DNA maintenance genes, including *BRCA1*, *BRCA2*, and *PALB2*, demonstrated that patients with pancreatic cancer with defective DNA maintenance genes responded better to platinum-based chemotherapy \[[@B13-ijms-19-03415]\]. In addition, preclinical studies led to the identification of potential therapeutic target genes. For example, downregulation of the microRNA, miR-98-5p promoted pancreatic tumor development by downregulation of MAP4K4 and inhibition of the downstream MAPK/ERK signaling, suggesting that the miR-98-5p can be a therapeutic target in pancreatic cancer treatment \[[@B14-ijms-19-03415]\]. Similarly, spalt-like protein 4 induced endothelial-mesenchymal transitions to facilitate metastatic potential in pancreatic ductal adenocarcinoma (PDAC) cells, indicating that spalt-like protein 4 might be a marker for PDAC treatment and that targeting this protein might benefit anti-proliferative and anti-metastasis therapies \[[@B15-ijms-19-03415]\]. A study demonstrated that the knockout of epithelial cell transforming 2 gene by the clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) gene editing method decreased proliferation and ability to migrate in the MiaPaCa2 pancreatic cancer cell line \[[@B16-ijms-19-03415]\]. Furthermore, three intratumoral infiltrating immune markers (CD15, CD206 and CD117) and one *SMAD4* mutation were found to be associated with recurrence and survival in patients after surgery for PDAC \[[@B17-ijms-19-03415]\] and G protein alpha-driven oncogenic mechanisms, Siks revealed unanticipated metabolic heterogeneity among *KRAS*-mutant pancreatic neoplasms and evidenced to be a potent tumor suppressor \[[@B18-ijms-19-03415]\].

Other preclinical studies, however, demonstrated the relationship of chemotherapy and gene expression \[[@B48-ijms-19-03415]\]. A study showing gemcitabine-mediated tumor regression and p53-dependent gene expression increased the possibility that targeting the Bax-dependent cell death pathway, rather than the PUMA pathway, might result in significantly improved patient outcomes and prognosis in pancreatic cancer \[[@B49-ijms-19-03415]\]. Intravenous administration of Rexin-G^TM^, a nonreplicative pathology-targeted retroviral vector bearing a cytocidal cyclin G1 construct, exhibited a good safety and efficacy profile in a phase I/II trial of gemcitabine-resistant pancreatic cancer \[[@B30-ijms-19-03415]\]. Intratumoral administration of CYL-02, a nonviral gene therapy product, using endoscopic ultrasound was found to be safe in a phase I trial including 22 patients who were concomitantly treated with gemcitabine \[[@B44-ijms-19-03415]\]. Conversely, RNAi therapy targeting *KRAS* in combination with chemotherapy showed efficacy in treating locally advanced pancreatic cancer patients \[[@B40-ijms-19-03415]\], whereas the G-protein-coupled receptor family C, member 5, group A gene was upregulated in PaCa cells, which led to enhanced drug resistance in PaCa cells \[[@B50-ijms-19-03415]\]. These data can aid in the implementation of personalized therapy for improved outcomes in patients with pancreatic cancer. In addition to pancreatic malignancies, ongoing studies are aimed to establish effective gene therapies for pancreatitis, pancreatic pain, and diabetes mellitus. Based on the several completed ([Table 1](#ijms-19-03415-t001){ref-type="table"}) and ongoing clinical trials \[[@B19-ijms-19-03415],[@B20-ijms-19-03415],[@B21-ijms-19-03415],[@B22-ijms-19-03415],[@B23-ijms-19-03415],[@B24-ijms-19-03415],[@B25-ijms-19-03415],[@B26-ijms-19-03415],[@B27-ijms-19-03415],[@B28-ijms-19-03415],[@B29-ijms-19-03415],[@B30-ijms-19-03415],[@B31-ijms-19-03415],[@B32-ijms-19-03415],[@B33-ijms-19-03415],[@B34-ijms-19-03415],[@B35-ijms-19-03415],[@B36-ijms-19-03415],[@B37-ijms-19-03415],[@B38-ijms-19-03415],[@B39-ijms-19-03415],[@B40-ijms-19-03415],[@B41-ijms-19-03415],[@B42-ijms-19-03415],[@B43-ijms-19-03415],[@B44-ijms-19-03415],[@B45-ijms-19-03415],[@B46-ijms-19-03415],[@B47-ijms-19-03415]\] ([Table 2](#ijms-19-03415-t002){ref-type="table"}), gene therapy offers a promising avenue as a safe and efficient approach \[[@B51-ijms-19-03415]\].

Various techniques used for gene therapy, including synthetic and viral vectors, molecular tools, such as interference RNA, and genome editing methods, showed promising results in filling the gap between experimental models of cancer and clinical trials \[[@B10-ijms-19-03415],[@B52-ijms-19-03415]\], therefore in this review, the methods of gene delivery into the pancreas used in studies are also summarized ([Table 3](#ijms-19-03415-t003){ref-type="table"}). This review summarizes the current landscape of completed and ongoing studies on these diseases for both the physicians and the researchers.

2. Pancreatic Cancer {#sec2-ijms-19-03415}
====================

The latest developments in pancreatic carcinoma gene therapy include gene-based tumor cell sensitization to chemotherapy, vaccination, and adoptive immunotherapy (chimeric antigen receptor T-cell \[CAR-T\] therapy). Furthermore, oncolytic virus therapies, including oncolytic adenoviruses, herpes virus, parvovirus, and reovirus are currently in development \[[@B10-ijms-19-03415]\].

Preclinical studies showed promising results in the efficacy of gene therapy. For example, the Lister strain of vaccinia virus armed with the endostatin-angiostatin fusion gene exhibited therapeutic efficacy for potential pancreatic cancer \[[@B53-ijms-19-03415]\], whereas the inhibition of miR-21 led to the inhibition of pancreatic cancer tumor growth both in vitro and in vivo \[[@B54-ijms-19-03415]\]. Additionally, introduction of decoy hyper-binding sites to sequester and suppress the entry of oncogenic HMGA1 into the nucleus of pancreatic cancer cells by replication-defective adenovirus serotype 5 virus achieved inhibition of cancer cell growth \[[@B55-ijms-19-03415]\].

Virus vectors used in these gene therapy studies include adeno-associated virus (AAV) vectors with capsids that are modified and optimized by site-directed mutagenesis to improve the transduction efficiency in the pancreatic tissue, especially in pancreatic cancer cells \[[@B56-ijms-19-03415]\]. Studies using oncolytic virus vectors utilize hexon modification to improve the activity of the oncolytic adenovirus vectors targeting the TGFBR to enable replication in tumor stromal cells as well \[[@B57-ijms-19-03415]\]. Targeted herpes simplex virus (HSV)-1 (HSV-1) whose expression is regulated by the cellular B-myb promoter in an experimental model of pancreatic tumor resulted in an effective reduction in tumor growth \[[@B58-ijms-19-03415]\]. However, in a phase II clinical trial, the progression-free survival rate was not improved in patients with metastatic pancreatic cancer who were treated with chemotherapy in combination with the oncolytic virus pelareorep, which causes oncolysis in pancreatic cells by activating Ras \[[@B42-ijms-19-03415]\]. On the other hand, oncosuppressive parvovirus H1 increased sensitivity to chemotherapy and inhibited the activation of the NFκB and the Akt/PI3K pathways in patients with pancreatic peritoneal carcinomatosis \[[@B59-ijms-19-03415]\].

Recent advances in the safety and efficacy of the CRISPR/Cas9 genome editing method \[[@B60-ijms-19-03415]\] led to several studies that investigated its utility in pancreatic cancer. For example, retrograde pancreatic ductal injection of adenoviral-Cre and lentiviral-Cre vectors were utilized to develop in vivo models of pancreatic cancer \[[@B61-ijms-19-03415]\]; this technique can significantly contribute to the establishment of novel therapies for pancreatic cancer.

Additional strategies utilizing gene targeting methods include cell therapies, such as T-cell programming \[[@B62-ijms-19-03415]\], immunotherapy, and CAR-T \[[@B63-ijms-19-03415],[@B64-ijms-19-03415]\]; induction of T-cell immunity to cancer antigens, such as mesothelin by GVAX pancreas; and granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor cells for pancreatic cancer patients with metastatic lesions \[[@B41-ijms-19-03415]\].

These studies are likely to change the clinical practice and approaches to PDAC management, as they represent a major advancement not only for PDAC, but also for the broader field of gene-based molecular treatment of cancer.

3. Pancreatitis {#sec3-ijms-19-03415}
===============

Pancreatitis, inflammation of the pancreas, can be classified into acute and chronic forms. Inflammation can be due to various factors, including alcohol, fatty food, gallstones, high serum calcium concentrations caused by the hyperparathyroidism, abdominal injury, chemotherapeutic agents, and pancreatic neoplasms. The etiological factor activates the pancreatic digestive enzymes in the pancreas itself instead of the small intestine. Abdominal pain, back pain, fever, nausea, and diarrhea are the major symptoms of pancreatitis, which may lead to abscess formation, infection, pseudocysts, multiple organ failure, malnutrition, diabetes mellitus, and pancreatic cancer.

Among the various etiologies, associations of genetic mutations with acute recurrent and chronic pancreatitis in children were reported \[[@B65-ijms-19-03415]\]. And gene therapy was studied in patients with genetic lipoprotein lipase deficiency-induced pancreatitis \[[@B66-ijms-19-03415]\]. Alipogene tiparvovec was tested in 19 patients with lipoprotein lipase deficiency, and the retrospective analysis of follow-up for up to 6 years after a single treatment demonstrated the association of alipogene tiparvovec with lower frequency and severity of pancreatitis events \[[@B66-ijms-19-03415]\]. In addition, the genetic association of recurrent autoimmune pancreatitis with resistance to steroid therapy is currently evaluated with NCT00444444. In this study, high-resolution typing for HLA with sequence-based typing is utilized to determine whether certain alleles or haplotypes of major histocompatibility complex gene are associated with autoimmune pancreatitis. Further analyses and trials will be conducted with the genomic information of this disease entity.

4. Pancreatic Pain {#sec4-ijms-19-03415}
==================

Abdominal pain is a major symptom associated with pancreatic diseases, and improvement of pain in acute pancreatitis is associated with the resolution of inflammation; however, pain related to pancreatic cancer and chronic pancreatitis persists and recurs and is therefore difficult to manage \[[@B67-ijms-19-03415]\]. The currently available management methods include analgesics, antioxidant micronutrients, drugs interfering with neural transmission, pancreatic enzymes, celiac plexus blockade, and surgery \[[@B67-ijms-19-03415]\]. As the severity of pain is associated with a decrease in quality of life, loss of appetite, and longer and frequent hospitalization and given that the development of various chemotherapeutic options for pancreatic cancer have led to a longer lifespan, it is essential to develop novel therapeutic options to manage pancreatic pain. Recent preclinical studies revealed that several neuroimmune and neuroplastic mechanisms, including infiltration of inflammatory cells, neural edema, perineural disruption, and neural hypertrophy, are involved as the underlying mechanisms of chronic pancreatitis pain \[[@B67-ijms-19-03415]\]. Furthermore, a recent study reported the contribution of the neuronal transforming growth factor beta (TGF-β) signaling mediated via neuronal SMAD3 to the development of pancreatic pain in an animal model \[[@B68-ijms-19-03415]\].

Based on these findings, a replication-defective herpes viral vector (HSV-1) construct encoding the human preproenkephalin (*ENK*) gene (HSV-ENK) was tested in a preclinical in vivo study \[[@B69-ijms-19-03415],[@B70-ijms-19-03415]\]. HSV-ENK was applied directly to the surface of the pancreas in rats with dibutyltin dichloride-induced pancreatitis rats, and their spontaneous behavioral activity was monitored. Compared with the controls, HSV-ENK-treated rats showed significantly increased expression of *ENK* in the pancreas, improved activity, and normalized FOS staining, indicating reduced neuronal activity \[[@B69-ijms-19-03415]\]. Similar results were shown in rat models of high-fat- and alcohol liquid diet-induced pancreatitis \[[@B70-ijms-19-03415]\]. Importantly, both studies showed the preservation of the acinar cells and amelioration of the inflammation, suggesting that this method might be potentially effective for not only pain control, but also pancreatic function in chronic pancreatitis.

The overexpression of TGF-β in mice and rats was associated with sensory neuron hyperexcitability, SMAD3 activation, and increase in nociception. As chronic pancreatitis leads to pancreatic fibrosis and that the TGF-β signaling pathway was shown to be associated with fibrosis, this signaling pathway can be utilized as a therapeutic target to reduce pain and fibrosis in patients with chronic pancreatitis \[[@B68-ijms-19-03415]\]. Given that the currently available treatment options are not sufficient to manage the severe pancreatic pain, development of new strategies are sorely needed.

5. Diabetes Mellitus {#sec5-ijms-19-03415}
====================

Diabetes mellitus is characterized by hyperglycemia arising from dysregulation of insulin and categorized into type 1, type 2, and gestational diabetes. The treatment approaches in diabetes depend on the type. Insulin replacement is used to treat patients with type 1 diabetes, which is caused by the impairment of pancreatic beta cells producing insulin. Type 2 diabetes is caused by an insufficient insulin level or hyposensitivity of the cells in the body to insulin, whereas gestational diabetes occurs in females during pregnancy and requires careful management to avoid complications in the child. Since chronic hyperglycemia leads dysfunction in various organs, including the vessels, heart, kidneys, retina, and the nervous system, careful management of blood glucose levels is necessary.

Genetic predisposition to diabetes has been reported in several studies. For example, mutation of neuronal differentiation 1, a basic helix-loop-helix transcription factor involved in the development of pancreas, can be found in patients with neonatal diabetes, as well as those with type 2 diabetes mellitus \[[@B71-ijms-19-03415]\]. Gene therapy approaches currently explored for diabetes mellitus include insulin gene therapy for type 1 diabetes mellitus, in which insulin expression in non-beta cells of the pancreas with hepatocytes emerged as the primary therapeutic target \[[@B72-ijms-19-03415]\]; fibroblast growth factor 21 (FGF21) gene therapy, which has showed promising results in a mouse model of metabolic disease \[[@B73-ijms-19-03415]\]; GLP-1 gene therapy, which improved insulin sensitivity and reduced abdominal and hepatic fat associated with obesity-induced diabetes mellitus and altered adipokine profiles \[[@B74-ijms-19-03415]\]; and in vivo reprogramming of pancreatic ductal cells by intraductal delivery of an adenoviral vector expressing transcription factors essential for beta cell function, which resulted in the induction of beta-like cells and correction of hyperglycemia \[[@B75-ijms-19-03415]\]. The combination of gene and cell therapy has also been reported to induce insulin-producing cells from the hepatocytes of newborn rats. In that study, analysis of miRNA expression the differentiation of hepatocytes to insulin-producing cells was associated with the BMP/Smad signaling pathway rather than the Wnt/β-catenin signaling pathway \[[@B76-ijms-19-03415]\]. More recently, transfection of Sarco-ER Ca^2+^-ATPase 2b gene in adipose mesenchymal stem cells exhibited a significant therapeutic effect in a mouse model of type 1 diabetes \[[@B77-ijms-19-03415]\]. Recent reports also showed the effect of FGF21 gene therapy on a high-fat-diet mouse model where treatment was associated with significant reductions in body weight, adipose tissue hypertrophy, insulin resistance, hepatic steatosis, inflammation, and fibrotic changes \[[@B78-ijms-19-03415]\]. That study used AAV vectors to mediate long-term and sustained protein production using liver-specific promoters, which resulted in sustained levels of circulating FGF21 for up to 1 year. Interestingly, FGF21 overexpression in normal mice fed with standard diet was also associated with the prevention of weight gain and insulin resistance related to aging \[[@B78-ijms-19-03415]\]. These preclinical studies illustrate the promising results of gene therapy for diabetes by targeting the pancreas.

6. Delivery Methods for Pancreatic Gene Therapy {#sec6-ijms-19-03415}
===============================================

The various methods for gene delivery used in clinical and preclinical studies of the pancreas can be classified into ex vivo and in vivo methods \[[@B79-ijms-19-03415]\]. Ex vivo gene transfer involves genetic modification of the cells harvested from the patients or experimental animals, which are then reintroduced to the patients or the animals. In vivo gene delivery methods can be further categorized into systemic administration and in situ delivery. The strategies of gene therapy for the pancreas are summarized in [Figure 1](#ijms-19-03415-f001){ref-type="fig"}.

Viral vectors used in studies thus far include oncoretrovirus, lentivirus, foamy virus, adenovirus, AAV, and HSV ([Table 1](#ijms-19-03415-t001){ref-type="table"} and [Table 2](#ijms-19-03415-t002){ref-type="table"}). The features of these viral vectors are summarized in [Table 3](#ijms-19-03415-t003){ref-type="table"}. Among these, the adenovirus and AAV vectors are commonly used as gene carriers in clinical trials ([Table 1](#ijms-19-03415-t001){ref-type="table"} and [Table 2](#ijms-19-03415-t002){ref-type="table"}). For example, an ongoing phase III trial (NCT00051467) is assessing whether TNFerade, a replication-deficient adenovirus vector that delivers tumor necrosis factor-alpha to tumor cells and is controlled by a chemoradiation-inducible promoter, in combination with 5-fluorouracil and radiation therapy will enhance their anti-tumor effect as first-line treatment of unresectable locally advanced pancreatic cancer.

For in vivo gene delivery, non-viral vector-based methods, including plasmid DNA injection, have also been utilized to deliver genes into target sites in the pancreas in clinical trials ([Table 1](#ijms-19-03415-t001){ref-type="table"} and [Table 2](#ijms-19-03415-t002){ref-type="table"}), whereas other non-viral vector-based methods, including chemical compound carriers and physical methods of gene delivery, have been tested in preclinical trials, as described earlier. Among the chemical approaches are cationic lipids, polymers, and chemically modified proteins, whereas simple needle injection, gene gun, electroporation, sonoporation, magnetofection, and hydrodynamic gene delivery are major methods of delivery by physical methods. The features of the gene delivery methods are also summarized in [Table 3](#ijms-19-03415-t003){ref-type="table"}. In addition to the currently ongoing clinical trials assessing plasmid gene injection, as well as viral vectors, a study (NCT02514421) is evaluating the efficacy and safety of electrochemotherapy using electroporation for the treatment of pancreatic cancer. Overall, these studies demonstrated the significance of the physical approach in clinical application. Furthermore, image-based guidance is essential for site-specific gene delivery in vivo, especially in the pancreas. Therefore, combination of gene delivery approaches with endoscopic ultrasound has been tested their safe and effective in situ delivery in pancreatic cancer \[[@B20-ijms-19-03415],[@B23-ijms-19-03415],[@B25-ijms-19-03415],[@B27-ijms-19-03415],[@B31-ijms-19-03415],[@B33-ijms-19-03415],[@B34-ijms-19-03415],[@B37-ijms-19-03415]\] ([Table 1](#ijms-19-03415-t001){ref-type="table"} and [Table 2](#ijms-19-03415-t002){ref-type="table"}). This technique has been successfully used in a clinic setting to block sympathetic innervation for the management of chronic pancreatic pain, wherein endoscopic ultrasound is used to inject neurolytic solutions to celiac plexus for neurolysis; this technique can be used to deliver genes. In the currently ongoing clinical trials, this technique has been combined with intratumoral injection of viral vectors, plasmids, and immunologically modified cells, among others ([Table 3](#ijms-19-03415-t003){ref-type="table"}).

A recent preclinical study by Kamimura et al. reported pancreas-targeted and specific hydrodynamic gene delivery through the superior mesenteric vein into the pancreas and demonstrated its efficacy and safety using naked DNA \[[@B80-ijms-19-03415]\]. Although the insertion of the catheter is essential, this clinically well-stablished physical and organ-specific gene delivery method can be used for both gene therapy studies and the establishment of pancreatic cancer animal models, in which oncogenic genes can be delivered to the pancreas to study various pancreatic tumor types for the development of appropriate therapeutic strategies. Another approach of siRNA delivery is ionizable low-molecular-weight polymeric nanoparticles, which has been demonstrated in nonhuman primates \[[@B81-ijms-19-03415]\]. That study showing endothelial gene silencing in multiple nonhuman primate organs using systemically administered siRNA nanoparticles highlights the potential of this approach for the treatment of disease in humans. Recent report showed that the autophagy is related to pancreatic cancer development and the disruption of the autophagy related gene and reduced autophagy related protein level contributed to inhibit the tumorigenesis. Therefore, the gene therapy managing the autophagy might be the additional option and the nucleic acids to control the gene expression is promising strategy \[[@B82-ijms-19-03415]\]. Further efforts are essential to develop and improve appropriate gene delivery methods for pancreatic diseases.

7. Clinical Trials {#sec7-ijms-19-03415}
==================

Building on preclinical studies, several clinical trials have been conducted to evaluate gene therapy in pancreatic diseases, especially pancreatic cancer \[[@B19-ijms-19-03415],[@B20-ijms-19-03415],[@B21-ijms-19-03415],[@B22-ijms-19-03415],[@B23-ijms-19-03415],[@B24-ijms-19-03415],[@B25-ijms-19-03415],[@B26-ijms-19-03415],[@B27-ijms-19-03415],[@B28-ijms-19-03415],[@B29-ijms-19-03415],[@B30-ijms-19-03415],[@B31-ijms-19-03415],[@B32-ijms-19-03415],[@B33-ijms-19-03415],[@B34-ijms-19-03415],[@B35-ijms-19-03415],[@B36-ijms-19-03415],[@B37-ijms-19-03415],[@B38-ijms-19-03415],[@B39-ijms-19-03415],[@B40-ijms-19-03415],[@B41-ijms-19-03415],[@B42-ijms-19-03415],[@B43-ijms-19-03415],[@B44-ijms-19-03415],[@B45-ijms-19-03415],[@B46-ijms-19-03415],[@B47-ijms-19-03415]\]. A summary of these studies can be found in [Table 1](#ijms-19-03415-t001){ref-type="table"}. Adenoviruses, plasmids, and synthetic vectors were used to deliver interleukin and suicide genes for therapeutic purposes. These genes were delivered by in situ injection with endoscopic ultrasound, intradermal or subcutaneous vaccination, or oncolytic virus injection. In addition, majority of these trials were coupled with chemotherapy or radiochemotherapy. Only one of these trials was a phase III study, and the remaining studies were phase I or II. The phase III trial was a randomized multi-institutional study conducted to assess the efficacy of TNFerade as a novel gene transfer method to deliver tumor necrosis factor-alpha to tumor cells, in combination with 5-fluorouracil and radiotherapy for locally advanced pancreatic cancer. TNFerade was injected intratumorally before the first fraction of radiotherapy using percutaneous transabdominal or endoscopic ultrasound \[[@B37-ijms-19-03415]\]. Although the anti-tumor effect of TNFerade was not significant, the approach was determined to be safe and confirmed to be usable in combination with the clinically well-established methods.

A summary of the currently ongoing trials can be found in [Table 2](#ijms-19-03415-t002){ref-type="table"} \[[@B51-ijms-19-03415]\]. These studies include gene therapy approaches using interleukin 13 and suicide genes; gene vaccination using plasmid DNA; and oncolytic viral gene therapy for pancreatic cancer, metastatic pancreatic cancer, pancreatic neuroendocrine tumor, and pancreatitis. In addition, cell therapies, including CAR-T for adoptive immunotherapy, are being evaluated in clinical trials. This system is considered as an adoptive active immunotherapy and autologous CD8 positive T cells are extracted from the patients and modified ex vivo to recognize and kill the cancer cells expressing the tumor antigen. There are more than 20 clinical trials still recruiting the candidate for the trials and newer trials will start continuously to develop the safe and effective gene therapy for the pancreatic diseases.

In these clinical trials on pancreatic diseases, standard methods of systemic administration and in situ gene transfer by infusion or electroporation, and site-specific administration using endoscopic ultrasound techniques are combined with various chemotherapies, including gemcitabine, cyclophosphamide, fludarabine, capecitabine, cisplatin, nab-paclitaxel, docetaxel, fluorouracil, sunitinib, and everolimus. For example, the clinical trial of NCT01274455 showed the safety of administration of non-viral gene product of CYL-02, which encodes mouse somatostatin receptor subtype 2 and a fusion gene of deoxycytidine kinase and monophosphate kinase, which could sensitize the cancer cells to gemcitabine \[[@B44-ijms-19-03415]\] and the clinical trial of NCT00836407 evaluated the effect of granulocyte-macrophage colony stimulating factor gene-delivered pancreatic tumor cells with the ipilimumab \[[@B47-ijms-19-03415]\]. This macrophage colony stimulating factor cold also been used for the cancer vaccine therapy \[[@B46-ijms-19-03415]\]. Majority of these trials are phase I or II, and further enrollment and assessment of the safety and efficacy is essential. However, pancreas-specific gene targeting can be achieved with the development of delivery methods, vectors, and clinical techniques. In addition, genome information-based precision medicine with mutation-targeted therapy is being tested in a phase II trial on advanced low- or intermediate-grade neuroendocrine tumors of the pancreas (NCT02315625).

8. Conclusions and Future Directions {#sec8-ijms-19-03415}
====================================

Pancreas is a key organ for digestion and endocrine function. Among the diseases affecting the pancreas, pancreatic cancer is a leading cause of cancer-related deaths worldwide. With the development of studies on gene therapy, various clinical trials are ongoing and showing the promising results, as well as in the basic preclinical researches for the gene delivery. With recent advances in promising technologies, such as the generation of induced pluripotent stem cells and gene editing by CRISPR/Cas9, development of delivery systems, carriers, and methods is essential. The findings of these studies and new methodologies that are developed for gene therapy can also be useful for currently untreatable pancreatic diseases and further studies to combine these methodologies will encourage new endeavor for the novel therapeutic options. For example, as in vivo gene editing based on CRISPR/Cas9, short-term transgene expression may be preferred, in order to prevent off-target effects, therefore, transient gene expression mediated by non-viral vector-based delivery methods might be advantageous over gene editing. While further investigation is needed to improve efficacy, with the advanced gene delivery methods armed with personal genomic information, these methods can be tailored to each patient based on specific biomarkers, which should ultimately improve prognosis and extend the life expectancy of the patients with pancreatic diseases.
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Summary of clinical trials published.

  No.   Ref.                       Conditions          Title                                                                                                                                                                                                                                 Carrier                           Interventions                                                              Phases            Enrollment
  ----- -------------------------- ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------- -------------------------------------------------------------------------- ----------------- ------------
  1     \[[@B19-ijms-19-03415]\]   Pancreatic Cancer   Gene therapy with Adv-IL-2 in unresectable digestive cancer: phase I-II study, intermediate report.                                                                                                                                   Adenovirus                        AdV/Interleukin 2                                                          Phase 1/Phase 2   7
  2     \[[@B20-ijms-19-03415]\]   Pancreatic Cancer   Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.                                                            Adenovirus                        AdV/ONYX-015                                                               Phase 1           23
  3     \[[@B21-ijms-19-03415]\]   Pancreatic Cancer   Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial.                                                                                                           Lipofectamine (Plasmid DNA)       Lipofectamine/Cyto. P450                                                   Phase 1/Phase 2   14
  4     \[[@B22-ijms-19-03415]\]   Pancreatic Cancer   Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial.                                                                                                                                     Cationic liposome (Plasmid DNA)   Cationic liposome/dendritic cells transfected with MUC1 cDNA               Phase 1/Phase 2   10
  5     \[[@B23-ijms-19-03415]\]   Pancreatic Cancer   A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.                                                                                     Adenovirus                        AdV/ONYX-015 + gemcitabine                                                 Phase 1/Phase 2   21
  6     \[[@B24-ijms-19-03415]\]   Pancreatic Cancer   First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.                                                                                                Retrovirus                        Rv/Rexin-G                                                                 Phase 1           3
  7     \[[@B25-ijms-19-03415]\]   Pancreatic Cancer   Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.                                                                                                                       Adenovirus                        AdV/Interleukin 12                                                         Phase 1           7
  8     \[[@B26-ijms-19-03415]\]   Pancreatic Cancer   TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.                                                            Adenovirus                        TNFerade                                                                   Phase 1           30
  9     \[[@B27-ijms-19-03415]\]   Pancreatic Cancer   Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.                                                                     Adenovirus                        Adv encoding interleukin-12 gene                                           Phase 1           11
  10    \[[@B28-ijms-19-03415]\]   Pancreatic Cancer   Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer.                                                                                                                                                          Vaccinia and Pox virus            Vaccinia and Pox virus expressing CEA MUC-1 and co-stimulatory molecules   Phase 1           10
  11    \[[@B29-ijms-19-03415]\]   Pancreatic Cancer   Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.   Plasmid DNA                       Plasmid/GVAX                                                               Phase 1           50
  12    \[[@B30-ijms-19-03415]\]   Pancreatic Cancer   Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.                                                                                            Retrovirus                        Rv/Rexin-G at two dosages                                                  Phase 1/Phase 2   9
  13    \[[@B31-ijms-19-03415]\]   Pancreatic Cancer   A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer.                                                          Herpes virus                      HF10 oncolytic herpes virus                                                Phase 1           6
  14    \[[@B32-ijms-19-03415]\]   Pancreatic Cancer   Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.                                                                   Immunotherapy                     Lymphocytes modified with an episomal EBV expressing Ras mutant            Phase 1           7
  15    \[[@B33-ijms-19-03415]\]   Pancreatic Cancer   Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer.                                                         Plasmid DNA                       Plasmid/expression of diphtheria-toxin gene                                Phase 1           9
  16    \[[@B34-ijms-19-03415]\]   Pancreatic Cancer   EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.                                                  Adenovirus                        AdV/TNFerade with chemoradiation                                           Phase 1           50
  17    \[[@B35-ijms-19-03415]\]   Pancreatic Cancer   A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.                                             Cancer vaccine                    Attenuated listeria vaccine                                                Phase 1           26
  18    \[[@B36-ijms-19-03415]\]   Pancreatic Cancer   Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.                                                                                                                        Immunotherapy                     Algenpantucel-L + gemcitabine + 5FU                                        Phase 2           70
  19    \[[@B37-ijms-19-03415]\]   Pancreatic Cancer   Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.                                                                         Adenovirus                        AdV/TNFerade + Chemoradiation Vs chemoradiation                            Phase 3           304
  20    \[[@B38-ijms-19-03415]\]   Pancreatic Cancer   Encapsulated cells expressing a chemotherapeutic activating enzyme allow the targeting of subtoxic chemotherapy and are safe and efficacious: data from two clinical trials in pancreatic cancer.                                     Lipofectamine (Plasmid DNA)       Lipofectamine/Cyto. P450                                                   Phase 2           13
  21    \[[@B39-ijms-19-03415]\]   Pancreatic Cancer   Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.                                                                                                                         Adenovirus                        AdV/HSV thymidine kinase                                                   Phase 1           24
  22    \[[@B40-ijms-19-03415]\]   Pancreatic Cancer   RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.                                                                                                                         RNAi                              SiG12-LODER^®^ + gemcitabine                                               Phase 1/Phase 2   15
  23    \[[@B41-ijms-19-03415]\]   Pancreatic Cancer   Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.                                                                              Cancer vaccine                    GVAX + CRS 2017                                                            Phase 2           90
  24    \[[@B42-ijms-19-03415]\]   Pancreatic Cancer   Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.                                                                                                   Reovirus                          Reolysin + paclitaxel + carboplatin                                        Phase 2           73
  25    \[[@B43-ijms-19-03415]\]   Pancreatic Cancer   AdV/Theragene + Chemotherapy                                                                                                                                                                                                          Adenovirus                        AdV/Theragene + Chemotherapy                                               Phase 1           9
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###### 

Summary of clinical trials ongoing.

  No.   Ref.                       NCT Number    Conditions                              Title                                                                                                                                                                                                                       Carrier                                                                                       Phases            Enrollment   Study Start      Study Completion
  ----- -------------------------- ------------- --------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- ----------------- ------------ ---------------- ------------------
  1                                NCT00415454   Pancreatic Cancer                       Study Combining Suicide Gene Therapy with Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma                                                                                                    Adenovirus                                                                                    Phase 1           8            November 2006    N/A
  2     \[[@B44-ijms-19-03415]\]   NCT01274455   Pancreatic Cancer                       Gene Therapy of Pancreatic Ductal Adenocarcinoma                                                                                                                                                                            Plasmid DNA                                                                                   Phase 1           22           December 2010    March 2013
  3                                NCT02806687   Pancreatic Cancer                       Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer                                                                                                                                     Plasmid DNA                                                                                   Phase 2           100          January 2017     June 2019
  4                                NCT02894944   Pancreatic Cancer                       Clinical Trial Phase I for Theragene in Combination with Chemotherapy for the Locally Advanced Pancreatic Cancer                                                                                                            Adenovirus                                                                                    Phase 1           9            August 2016      July 2018
  5     \[[@B45-ijms-19-03415]\]   NCT00121745   Pancreatic Cancer                       Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer                                                                                                                                                Retrovirus                                                                                    Phase 1           12           July 2005        July 2007
  6                                NCT03165188   Pancreatic Cancer                       Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy                                                                                                          Immunotherapy                                                                                 Not Applicable    500          September 2017   June 2031
  7                                NCT01583686   Pancreatic Cancer                       CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer                                                                                                                                  CAR-T                                                                                         Phase 1/Phase 2   136          April 2012       December 2028
  8                                NCT02830724   Pancreatic Cancer                       Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD71 Expressing Cancers                                                                                  CAR-T                                                                                         Phase 1/Phase 2   113          April 2017       January 2028
  9                                NCT00638612   Pancreatic Cancer                       AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK02)                                                                                                                                                 Adenovirus                                                                                    Phase 1           27           August 2008      June 2015
  10                               NCT02465983   Pancreatic Cancer                       Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer                                                                                                                                             CAR-T                                                                                         Phase 1           4            May 2015         November 2017
  11                               NCT03190941   Pancreatic Cancer                       Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A\*1102 Patients                                                                     Immunotherapy                                                                                 Phase 1/Phase 2   110          September 2017   June 2028
  12                               NCT03225989   Pancreatic Cancer                       Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer                                                                                                                                                    Adenovirus                                                                                    Phase 1/Phase 2   50           March 2018       December 2022
  13                               NCT03192462   Pancreatic Cancer                       TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer                                                                                                                                                     Immunotherapy                                                                                 Phase 1/Phase 2   45           January 2018     November 2025
  14                               NCT00004178   Pancreatic Cancer                       Gene Therapy in Treating Patients With Cancer                                                                                                                                                                               Immunotherapy                                                                                 Phase 1           null         April 1998       December 2001
  15    \[[@B46-ijms-19-03415]\]   NCT00084383   Pancreatic Cancer                       Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas                                                                     Cancer vaccine                                                                                Phase 2           60           January 2002     July 2006
  16    \[[@B47-ijms-19-03415]\]   NCT00836407   Pancreatic Cancer                       Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer                                                                                                     Cancer vaccine                                                                                Phase 1           30           February 2009    July 2012
  17                               NCT00305760   Pancreatic Cancer                       Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer                                                                                                 Cancer vaccine                                                                                Phase 2           60           December 2005    N/A
  18                               NCT02750657   Pancreatic Cancer                       Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection                                                                                                             Genetic Profiling                                                                             Not Applicable    180          December 2015    December 2021
  19                               NCT00303927   Pancreatic Cancer                       Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene                                                                                             Genetic Profiling                                                                             Phase 2           65           December 2005    N/A
  20                               NCT01188109   Pancreatic Cancer                       Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC2 in Treatment Decision                                                                                                                    Genetic Profiling                                                                             Phase 2           25           July 2010        July 2015
  21                               NCT00389610   Pancreatic Cancer                       Vaccine Therapy in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery                                                                                                                                Cancer vaccine                                                                                Phase 2           56           September 2006   December 2018
  22                               NCT01394120   Pancreatic Cancer                       Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer                                                                                                                                          For Targeted and Tailored Treatment                                                           Phase 2           60           August 2011      December 2013
  23                               NCT00066404   Pancreatic Cancer                       Intrapleural BG00002 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions                                                                                                                Recombinant adenovirus                                                                        Phase 1           null         April 2003       N/A
  24                               NCT01474564   Pancreatic Cancer                       Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma                                                                                                        Genetic Profiling                                                                             Not Applicable    60           November 2011    November 2019
  25                               NCT02405585   Pancreatic Cancer                       Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer                                                                                                                                                     Immunotherapy                                                                                 Phase 2           10           April 2015       N/A
  26                               NCT02705196   Pancreatic Cancer                       LOAd704 Oncolytic Virus Therapy for Pancreatic Cancer                                                                                                                                                                       Adenovirus                                                                                    Phase 1/Phase 2   26           November 2016    August 2019
  27                               NCT00669734   Pancreatic Cancer                       Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery                                                                                                                Cancer vaccine                                                                                Phase 1           18           February 2010    N/A
  28                               NCT00727441   Pancreatic Cancer                       Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery                                Cancer vaccine                                                                                Not Applicable    87           July 2008        March 2018
  29                               NCT00947102   Pancreatic Cancer                       Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer                                                                                                              Observation                                                                                   Not Applicable    null         February 2009    December 2011
  30                               NCT00051467   Pancreatic Cancer                       A Study of TNFerade Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer                                                                                    Adenovirus                                                                                    Phase 3           null         N/A              N/A
  31                               NCT03531125   Pancreatic Cancer                       Gene Expression in Resectable Pancreatic Cancer                                                                                                                                                                             Procedure of Endoscopic Ultrasound                                                            Not Applicable    10           June 2018        December 2019
  32                               NCT00429858   Pancreatic Cancer                       Gemcitabine and S-2 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer                                                                                                                                       Chemotherapy                                                                                  Phase 2           21           January 2007     October 2010
  33                               NCT02568267   Pancreatic Cancer                       Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS2, or ALK Gene Rearrangements (Fusions)                                                         Genetic Profiling                                                                             Phase 2           300          November 2015    October 2020
  34                               NCT00159471   Pancreatic Cancer                       Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.                                                                                          Genetic Profiling                                                                             Not Applicable    1            February 2005    July 2006
  35                               NCT00386399   Pancreatic Cancer                       Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA3 Gene                                                                                                                       Genetic Profiling                                                                             Phase 2           0            October 2006     February 2008
  36                               NCT01836432   Pancreatic Cancer                       Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer                                                                                                                             Immunotherapy                                                                                 Phase 3           302          May 2013         June 2017
  37                               NCT00255827   Pancreatic Cancer                       Vaccine Treatment for Surgically Resected Pancreatic Cancer                                                                                                                                                                 Cancer vaccine                                                                                Phase 1/Phase 2   7            November 2005    September 2007
  38                               NCT01938716   Pancreatic Cancer                       Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy                                                                                                                                                      Chemotherapy                                                                                  Not Applicable    40           March 2012       March 2019
  39                               NCT03193190   Pancreatic Cancer                       A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)                                                                Immunotherapy                                                                                 Phase 1/Phase 2   185          July 2017        September 2020
  40                               NCT00089024   Pancreatic Cancer                       Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer                                                                                                                Chemotherapy                                                                                  Phase 2           50           February 2004    N/A
  41                               NCT02465060   Pancreatic Cancer                       Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)                                                         Genetic Profiling                                                                             Phase 2           6452         August 2015      N/A
  42                               NCT01191684   Pancreatic Cancer                       Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer                                                                                                                                         Cancer vaccine                                                                                Phase 1           12           October 2011     August 2013
  43                               NCT01088789   Pancreatic Cancer                       A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine                                                                                                                                                              Plasmid DNA                                                                                   Phase 2           72           April 2010       April 2023
  44                               NCT02514421   Pancreatic Cancer                       Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma                                                                                                                      Device of Electroporation                                                                     Not Applicable    24           July 2015        July 2017
  45                               NCT02414100   Pancreatic Cancer                       Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy                                           Genetic Profiling                                                                             Not Applicable    0            December 2013    December 2016
  46                               NCT00936104   Pancreatic Cancer                       Side Population in Pancreatic Ductal Adenocarcinoma (PDAC)                                                                                                                                                                                                                                                                Not Applicable    20           August 2008      July 2012
  47                               NCT03302637   Pancreatic Cancer                       Oral Microbiome and Pancreatic Cancer                                                                                                                                                                                       Genetic Profiling                                                                             Not Applicable    732          December 1992    December 2010
  48                               NCT03602079   Pancreatic Cancer                       Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER3 Gene                                                                                                            Genetic Profiling                                                                             Phase 1/Phase 2   82           July 2018        May 2021
  49                               NCT03337087   Pancreatic Cancer                       Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer                                                      Chemotherapy                                                                                  Phase 1/Phase 2   110          August 2018      December 2022
  50                               NCT00128622   Pancreatic Cancer                       Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer                                                                                                                                 Cancer vaccine                                                                                Phase 1           24           September 2005   May 2009
  51                               NCT02592395   Pancreatic Cancer                       Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma                                                                                                                                       Device of Electroporation                                                                     Phase 1           0            October 2015     October 2017
  52                               NCT02432963   Pancreatic Cancer                       Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy                                                                                                                     Cancer vaccine                                                                                Phase 1           19           November 2015    February 2019
  53                               NCT00959946   Pancreatic Cancer                       Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer                                                                                                                       Chemotherapy                                                                                  Phase 1/Phase 2   32           September 2009   March 2011
  54                               NCT01643499   Pancreatic Cancer                       Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies                                                                                             Genetic Profiling                                                                             Phase 1           79           March 2012       August 2020
  55                               NCT02576665   Pancreatic Cancer                       A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 7)                                                                                              Retrovirus                                                                                    Phase 1           30           July 2016        November 2019
  56                               NCT00711997   Pancreatic Cancer                       Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer                                                                                                                                                          Plasmid DNA                                                                                   Phase 1/Phase 2   9            August 2009      December 2010
  57                               NCT02239861   Pancreatic Cancer                       TAA-Specific CTLS for Solid Tumors (TACTASOM)                                                                                                                                                                               Immunotherapy                                                                                 Phase 1           16           April 2015       December 2018
  58                               NCT03281382   Metastatic Pancreatic Cancer            Phase 1 Trial of Interleukin 13 Gene Therapy for Metastatic Pancreatic Cancer                                                                                                                                               Adenovirus                                                                                    Phase 1           9            July 2017        June 2021
  59                               NCT02340117   Metastatic Pancreatic Cancer            Study of Combined SGT-54 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer                                                                                                                                   Immunotherapy                                                                                 Phase 2           28           January 2015     December 2020
  60                               NCT00868114   Metastatic Pancreatic Cancer            Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer                                                                                                                                         Cell                                                                                          Phase 2           35           July 2006        December 2015
  61                               NCT01437007   Metastatic Pancreatic Cancer            TKM 080302 for Primary or Secondary Liver Cancer                                                                                                                                                                            RNAi                                                                                          Phase 1           1            August 2011      June 2012
  62                               NCT02416466   Metastatic Pancreatic Cancer            CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases                                                                                                                                                         CAR-T                                                                                         Phase 1           8            April 2015       January 2019
  63                               NCT01116791   Peritoneal Carcinomatosis               Cytoreductive Surgery (CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer                                             Procedure of Cytoreductive Surgery plus Hyperthermic Intraoperative Peritoneal Chemotherapy   Phase 2           34           July 2010        December 2015
  64                               NCT02315625   Neuroendocrine Tumors of the Pancreas   Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery   Genetic Profiling                                                                             Phase 2           120          April 2015       December 2025
  65                               NCT00444444   Pancreatitis                            Genetic Analysis for Predicting of Relapse During Steroid Treatment for Autoimmune Pancreatitis (AIP)                                                                                                                                                                                                                                       40           February 2002    June 2007
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###### 

Gene delivery methods used in clinical and pre-clinical stages.

  Gene Transfer Methods                      Functional Component                                         Targeted Genes                                                              Features                                                                          Features
  ------------------------------------------ ------------------------------------------------------------ --------------------------------------------------------------------------- --------------------------------------------------------------------------------- ----------
  **Viral Vectors**                                                                                       Tumor suppressor genes, Pro-apoptotic genes, Suicide genes, siRNA, miRNA,                                                                                     
  Oncoretrovirus                             RNA                                                          High efficiency                                                             Random integration, low titer                                                     
  Lentivirus                                 RNA                                                          High efficiency, sustained gene expression                                  Random integration, low titer                                                     
  Foamy virus                                RNA                                                          High efficiency, sustained gene expression                                  Random integration, low titer                                                     
  Adenovirus                                 Double stranded DNA                                          High efficiency, sustained gene expression, infect non-dividing cells       Host innate immune response                                                       
  Adeno-associated virus                     Single stranded DNA                                          No pathogenic, sustained gene expression, infect to non-dividing cells      Integration may occur, small capacity of transgene, low titer                     
  Herpes simplex virus                       Double stranded DNA                                          No integration, sustained gene expression                                   Low transduction efficiency                                                       
  **Non-viral Vectors (Chemicals)**                                                                                                                                                                                                                                     
  Lipids                                     Cationic lipids                                              High efficiency in vitro, ease to prepare                                   Low efficiency in vivo, acute immune response                                     
  Polymers                                   Cationic polymers                                            Highly effective in vitro, ease to prepare                                  Toxic to cells, acute immune response                                             
  Proteins                                   Natural or chemically modified proteins in cationic nature   Highly effective in vitro, less toxic, can be target specific               Low activity in vivo                                                              
  Peptides                                   Lysine or arginine residues in peptides                      Highly effective in vitro, less toxic, can be target specific               Low activity in vivo                                                              
  **Non-viral Vectors (Physical Methods)**                                                                                                                                                                                                                              
  Needle injection                           Mechanic force                                               Simple                                                                      Low efficiency, expression limited to needle track                                
  Gene gun                                   Pressure                                                     Good efficiency                                                             Limited to target area, need surgical procedure for internal organ                
  Electroporation                            Electric pulse                                               High efficiency                                                             Tissue damage, limited target area, need surgical procedure for internal organ    
  Sonoporation                               Ultrasound                                                   Site specific                                                               Low efficiency, tissue damage                                                     
  Magnetofection                             Magnetic field                                               Site specific                                                               Low efficiency, limited target area, need surgical procedure for internal organ   
  Hydrodynamic delivery                      Hydrodynamic pressure                                        Simple, high efficiency, site specific                                      Need catheter insertion technique in large animals                                
  **Immunotherapy**                          Cytokines                                                                                                                                Require ex vivo cell culture                                                      
  **Adoptive Immunotherapy**                 CAR-T                                                                                                                                    Require ex vivo cell culture                                                      
  **Vaccination**                            Antigen-pulsed dendritic cells                                                                                                           Intravenous or subcutaneous or local administration                               
